NF1 and colorectal carcinoma: Although genetic alterations in the PI3K and RAS/MAPK pathways are common in CRC and NF1 alterations have been detected in 5–6% of cases, it remains unclear as to whether NF1 mutations in CRC are related to chemotherapeutic effect.